复发难治成人弥漫大B细胞淋巴瘤CAR-T治疗的成本效果分析
该研究采用决策分析马尔可夫模型,基于美国支付方视角评估 axi-cel 和 tisagenlecleucel 在多线复发/难治成人弥漫大B细胞淋巴瘤中的成本效果。在乐观情景假设下,axi-cel 和 tisagenlecleucel 分别增加生命年并获 QALY,增量成本效果比可能低于 $150,000/QALY,但取决于长期结局的不确定性;广泛使用将显著增加医疗费用。
要点
- 在 40% 5 年 PFS 乐观假设下,axi-cel 增加 8.2 生命年,$129,000/QALY(95% UI $90,000–$219,000)。
- 在 35% 5 年 PFS 乐观假设下,tisagenlecleucel 增加 4.6 生命年,$168,000/QALY(95% UI $105,000–$414,000/QALY)。
- 降价至 $250,000/$200,000 或仅对初始完全缓解付费,可使 ICER 低于 $150,000/QALY。
核心结论
- 在 2018 年价格下,两种 CAR-T 疗法均可能满足低于 $150,000/QALY 的阈值,但这取决于与化疗免疫治疗和干细胞移植相比的长期结局,而后者尚不确定。
- 广泛采用将大幅增加非霍奇金淋巴瘤的医疗费用。
- 降价或仅对初始缓解付费可改善成本效果,即使在长期结局 modest 的情况下。
研究设计与样本
- 研究使用决策分析马尔可夫模型,基于近期多中心单臂试验数据,评估 axi-cel 和 tisagenlecleucel 在多线复发/难治成人弥漫大B细胞淋巴瘤中的成本效果。
- 研究采用美国医疗支付方视角,终身时间 horizon,并与挽救性化疗免疫治疗方案及干细胞移植进行比较。
- 主要结局包括未贴现生命年、贴现终身成本、贴现质量调整生命年(QALY)和增量成本效果比,年贴现率为 3%。
- 研究进行了敏感性分析以探索不确定性。
主要发现
- 在乐观情景下(假设 40% 5 年 PFS),axi-cel 增加 8.2 生命年,$129,000/QALY(95% UI $90,000–$219,000)。
- 在 30% 5 年 PFS 假设下,axi-cel 增加 6.4 生命年,$159,000/QALY(95% UI $105,000–$284,000)。
- 在乐观情景下(假设 35% 5 年 PFS),tisagenlecleucel 增加 4.6 生命年,$168,000/QALY(95% UI $105,000–$414,000/QALY)。
- 在 25% 5 年 PFS 假设下,tisagenlecleucel 增加 3.4 生命年,$223,000/QALY(95% UI $123,000–$1,170,000/QALY)。
- 对所有适应症患者施用 CAR-T 将在 5 年内增加美国医疗费用约 $10 billion。
临床怎么用
- 在 2018 年价格下,axi-cel 和 tisagenlecleucel 可能满足低于 $150,000/QALY 的阈值,但取决于与化疗免疫治疗和干细胞移植相比的长期结局。
- 价格降至 $250,000(axi-cel)和 $200,000(tisagenlecleucel),或仅对初始完全缓解付费(当前价格),可使两种疗法在 25% PFS 下仍低于 $150,000/QALY。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; each costs $373,000. We evaluated their cost effectiveness. METHODS: We used a decision analytic Markov model informed by recent multicenter, single-arm trials to evaluate axi-cel and tisagenlecleucel in multiply relapsed/refractory, adult, diffuse large B-cell lymphoma from a US health payer perspective over a lifetime horizon. Under a range of plausible long-term effectiveness assumptions, each therapy was compared with salvage chemoimmunotherapy regimens and stem-cell transplantation. Main outcomes were undiscounted life years, discounted lifetime costs, discounted quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (3% annual discount rate). Sensitivity analyses explored uncertainty. RESULTS: In an optimistic scenario, assuming a 40% 5-year progression-free survival (PFS), axi-cel increased life expectancy by 8.2 years at $129,000/QALY gained (95% uncertainty interval, $90,000 to $219,000). At a 30% 5-year PFS, improvements in life expectancy were more modest (6.4 years) and expensive ($159,000/QALY gained [95% uncertainty interval, $105,000 to $284,000]). In an optimistic scenario, assuming a 35% 5-year PFS, tisagenlecleucel increased life expectancy by 4.6 years at $168,000/QALY gained (95% uncertainty interval, $105,000 to $414,000/QALY). At a 25% 5-year PFS, improvements in life expectancy were smaller (3.4 years) and more expensive ($223,000/QALY gained [95% uncertainty interval, $123,000 to $1,170,000/QALY]). Administering CAR-T to all indicated patients would increase US health care costs by approximately $10 billion over 5 years. Price reductions to $250,000 and $200,000, respectively, or payment only for initial complete response (at current prices) would allow axi-cel and tisagenlecleucel to cost less than $150,000/QALY, even at 25% PFS. CONCLUSION: At 2018 prices, it is possible that both CAR-T therapies meet a less than $150,000/QALY threshold. This depends on long-term outcomes compared with chemoimmunotherapy and stem-cell transplantation, which are uncertain. Widespread adoption would substantially increase non-Hodgkin lymphoma health care costs. Price reductions or payment for initial response would improve cost effectiveness, even with modest long-term outcomes.
引用
- Lin JK, Muffly LS, Spinner MA, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019. PMID: 31157579. doi:10.1200/JCO.18.02079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。